Cell-free heme (CFH)

Cell-free heme is a potent pro-oxidant and pro-inflammatory molecule released into the circulation during hemolysis or extensive tissue damage [Chiabrando et al., 2014; Jeney et al., 2002]. While intracellular heme is a vital prosthetic group for hemoproteins like hemoglobin, its extracellular presence acts as a damage-associated molecular pattern (DAMP) that triggers innate immune responses via the Toll-like receptor 4 (TLR4) pathway [Figueiredo et al., 2007]. This activation leads to the production of pro-inflammatory cytokines and promotes vaso-occlusion, particularly in the context of sickle cell disease and malaria [Belcher et al., 2014; Larsen et al., 2010]. Furthermore, the iron atom within the porphyrin ring of cell-free heme catalyzes the formation of reactive oxygen species (ROS), leading to lipid peroxidation and endothelial dysfunction [Jeney et al., 2002]. Therapeutic strategies focus on neutralizing this toxicity using scavenger proteins such as hemopexin, which binds heme with extremely high affinity and facilitates its clearance via the CD91 receptor [Schaer et al., 2014]. Monitoring plasma heme and endogenous hemopexin levels serves as a critical biomarker strategy for assessing disease severity and therapeutic efficacy in hemolytic conditions [Muller-Eberhard et al., 1968; Kato et al., 2017].

Other names

Labile hemeExtracellular hemeNon-protein-bound hemeFerriprotoporphyrin IXHeme

The primary therapeutic mechanism involves the high-affinity sequestration and neutralization of cell-free heme by scavenger proteins like hemopexin, which prevents heme from activating the TLR4 pathway and participating in Fenton chemistry-mediated oxidative damage [Schaer et al., 2014; Figueiredo et al., 2007]. Additionally, pharmacological induction of Heme Oxygenase-1 (HO-1) facilitates the enzymatic degradation of cell-free heme into biliverdin, carbon monoxide, and iron, thereby mitigating its toxic effects [Wagener et al., 2013].